Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 7685 results

  1. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

    In development [GID-TA10893] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

    In development [GID-NG10419] Expected publication date: 31 March 2025

    NICE guideline
    In development

  3. Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)

    In development [GID-NG10415] Expected publication date: TBC

    NICE guideline
    In development

  4. Obinutuzumab for treating lupus nephritis ID 6420

    Awaiting development [GID-TA11478] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 28 January 2025

    Technology appraisal guidance
    In development

  6. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Molnupiravir for treating COVID-19 [ID6340]

    In development [GID-TA11409] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  8. Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment

    In development [GID-HTE10027] Expected publication date: 08 January 2025

    Health technology evaluations
    In development

  9. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  10. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  11. Efgartigimod for treating generalised myasthenia gravis [ID4003]

    In development [GID-TA10986] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

    In development [GID-TA10948] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

    Awaiting development [GID-TA10682] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Fertility problems: assessment and treatment

    In development [GID-NG10263] Expected publication date: 06 August 2025

    NICE guideline
    In development

  15. Maternal and child nutrition

    In development [GID-NG10191] Expected publication date: 15 January 2025

    NICE guideline
    In development